DermTech (BMV:DMTK *) - Cotización, noticias y análisis

Resumen de acción DMTK *

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.

Acerca de la empresa

DMTK * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 29.43%

Análisis de riesgos

Acciones altamente ilíquidas

No tiene una capitalización de mercado significativa (MX$52M)

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de DermTech, Inc.

Noile-Immune Biotech

TSE:4893

JP¥7.0b

Actinogen Medical

ASX:ACW

AU$67.5m

Aadi Bioscience

NasdaqCM:AADI

US$43.7m

Zenotech Laboratories

BSE:532039

₹4.2b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for DermTech
Historical stock prices
Current Share Price	US$55.65
52 Week High	US$55.65
52 Week Low	US$55.65
Beta	2.69
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-96.59%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	DMTK *	MX Biotechs	Mercado MX
7D	0%	0%	0%
1Y	n/a	0%	0%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de DMTK * en comparación con el sector MX Biotechs .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de DMTK * frente al mercado MX.

Volatilidad de los precios

Is DMTK *'s price volatile compared to industry and market?
DMTK * volatility
DMTK * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: DMTK * no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de DMTK * en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	279	Bret Christensen	www.dermtech.com

Resumen de fundamentos de DermTech, Inc.

¿Cómo se comparan los beneficios e ingresos de DermTech con su capitalización de mercado?
Estadísticas fundamentales de DMTK *
Capitalización bursátil	Mex$943.27m
Beneficios(TTM)	-Mex$2.18b
Ingresos (TTM)	Mex$255.05m

3.7x

Ratio precio-ventas (PS)

-0.4x

Ratio precio-beneficio (PE)

¿Está DMTK * sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DMTK *
Ingresos	US$14.02m
Coste de los ingresos	US$14.84m
Beneficio bruto	-US$813.00k
Otros gastos	US$118.82m
Beneficios	-US$119.63m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.55
Margen bruto	-5.80%
Margen de beneficio neto	-853.02%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado DMTK * a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción DMTK *

Recompensas

Análisis de riesgos

Competidores de DermTech, Inc.

TSE:4893

JP¥7.0b

ASX:ACW

AU$67.5m

NasdaqCM:AADI

US$43.7m

BSE:532039

₹4.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Recent updates

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

DermTech, Inc. Announces Change of CEO

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

DermTech, Inc. Announces Board Committee Appointments

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Chief Operating Officer recently sold Mex$292k worth of stock

High number of new directors

Second quarter 2022 earnings released: US$0.99 loss per share (vs US$0.59 loss in 2Q 2021)

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

High number of new and inexperienced directors

Dermtech Announces New Board Appointment

High number of new and inexperienced directors

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech, Inc. announced delayed annual 10-K filing

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new and inexperienced directors

DermTech, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new and inexperienced directors

President recently sold Mex$687k worth of stock

Chief Operating Officer recently sold Mex$1.3m worth of stock

High number of new and inexperienced directors

DermTech Unveils DermTech Stratum

Third quarter 2021 earnings released: US$0.68 loss per share (vs US$0.50 loss in 3Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$3.1m worth of stock

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.58 loss in 2Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$2.5m worth of stock

President recently sold Mex$7.6m worth of stock

Dermtech, Inc. Provides Earnings Results for the Second Quarter of 2021

DermTech, Inc. Provides No Financial Guidance for the Fiscal Year 2021

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de DermTech, Inc.

3.7x

-0.4x

Beneficios e Ingresos